Sanofi, Exscientia link to develop bispecific small molecule drugs

Under the alliance, Exscientia will use its platform to seek out and validate combinations of drug targets that could work synergistically and be amenable to its bispecific-small-molecule design strategy.

Spotlight

Spotlight

Related News